Adult patients with relapsed or refractory large B-cell lymphoma after two or more previous treatments. Patients with relapsed aBNHL who were treated with tisagenlecleucel in the BELINDA trial are compared with the current standard of care for patients with relapsed aggressive B-cell non-Hodgkin lymphoma (aBNHL). These patients had worse outcomes at Week 12 after receiving tisagenlecleucel, compared with patients receiving standard of care.

Patients up to 25 years old with acute lymphoblastic leukemia that is refractory to fight cancer:

- More patients in the tisagenlecleucel group had disease that was progressing compared with patients receiving standard of care.
- The safety profile of tisagenlecleucel was also compared with standard of care.
- Results from the BELINDA trial: the effectiveness of tisagenlecleucel was compared with the current standard of care within 1 year of initial treatment have very poor outcomes.

Acknowledgments

3. References

- Tisagenlecleucel is approved for:

  - T-cell (type: autologous)

- Tisagenlecleucel is manufactured for each individual patient by using their own T-cells.

- A form of B-cell lymphoma that grows quickly:

  - High-grade B-cell lymphoma

- Disorders that affect the blood; for example, problems with blood cells or organs that produce blood cells:

  - Hematologic disorders

- Grade 3 or higher adverse event:

  - Grade 3 or higher adverse event

- An occurrence that signifies that a cancer treatment has stopped working, either because the tumor is no longer shrinking or because it is growing; death is also considered an event:

  - Disease progression

- Grade 3 or higher adverse events:

  - Fever
  - Neuropathy
  - Urticaria
  - Anaphylaxis

- Infections:

  - 17%

- Grade 3 or higher treatment related:

  - 86%

- The newly created tisagenlecleucel T-cells specific molecules (called CD19) on cancer cells.

- Cryopreservation:

  - 3

- A procedure where a patient's healthy stem cells are removed from their body, the patient receives very high doses of chemotherapy to kill more than half of patients will not receive a stem cell transplant or has relapsed.

- Stem cell transplant:

  - 52

- Days:

  - 75

- Months:

  - 18

- Days:

  - 65

- Days:

  - 29

- Months:

  - 10

- Months:

  - 14

- Months:

  - 6

- Months:

  - 1

- Months:

  - 2

- Months:

  - 4

- Months:

  - 8

- Months:

  - 12

- Months:

  - 17

- Months:

  - 25

- Months:

  - 35

- Months:

  - 52

- Months:

  - 75

- Months:

  - 100

- Months:

  - 125

- Months:

  - 150

- Months:

  - 175

- Months:

  - 200

- Months:

  - 225

- Months:

  - 250

- Months:

  - 275

- Months:

  - 300

- Months:

  - 325

- Months:

  - 350

- Months:

  - 375

- Months:

  - 400

- Months:

  - 425

- Months:

  - 450

- Months:

  - 475

- Months:

  - 500

- Months:

  - 525

- Months:

  - 550

- Months:

  - 575

- Months:

  - 600

- Months:

  - 625

- Months:

  - 650

- Months:

  - 675

- Months:

  - 700

- Months:

  - 725

- Months:

  - 750

- Months:

  - 775

- Months:

  - 800

- Months:

  - 825

- Months:

  - 850

- Months:

  - 875

- Months:

  - 900

- Months:

  - 925

- Months:

  - 950

- Months:

  - 975

- Months:

  - 1000

- Months:

  - 1025

- Months:

  - 1050

- Months:

  - 1075

- Months:

  - 1100

- Months:

  - 1125

- Months:

  - 1150

- Months:

  - 1175

- Months:

  - 1200

- Months:

  - 1225

- Months:

  - 1250

- Months:

  - 1275

- Months:

  - 1300

- Months:

  - 1325

- Months:

  - 1350

- Months:

  - 1375

- Months:

  - 1400

- Months:

  - 1425

- Months:

  - 1450

- Months:

  - 1475

- Months:

  - 1500

- Months:

  - 1525

- Months:

  - 1550

- Months:

  - 1575

- Months:

  - 1600

- Months:

  - 1625

- Months:

  - 1650

- Months:

  - 1675

- Months:

  - 1700

- Months:

  - 1725

- Months:

  - 1750

- Months:

  - 1775

- Months:

  - 1800

- Months:

  - 1825

- Months:

  - 1850

- Months:

  - 1875

- Months:

  - 1900

- Months:

  - 1925

- Months:

  - 1950

- Months:

  - 1975

- Months:

  - 2000

- Months:

  - 2025

- Months:

  - 2050

- Months:

  - 2075

- Months:

  - 2100

- Months:

  - 2125

- Months:

  - 2150